- Home
- APM vs PTIX Comparison
APM vs PTIX Comparison
Compare APM & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- PTIX
- Stock Information
- Founded
- APM 2010
- PTIX 1994
- Country
- APM United Kingdom
- PTIX United States
- Employees
- APM N/A
- PTIX N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- PTIX Health Care
- Exchange
- APM Nasdaq
- PTIX Nasdaq
- Market Cap
- APM 4.1M
- PTIX 3.7M
- IPO Year
- APM 2018
- PTIX 2016
- Fundamental
- Price
- APM $1.15
- PTIX $0.44
- Analyst Decision
- APM
- PTIX
- Analyst Count
- APM 0
- PTIX 0
- Target Price
- APM N/A
- PTIX N/A
- AVG Volume (30 Days)
- APM 7.0M
- PTIX 377.2K
- Earning Date
- APM 12-20-2024
- PTIX 11-14-2024
- Dividend Yield
- APM N/A
- PTIX N/A
- EPS Growth
- APM N/A
- PTIX N/A
- EPS
- APM 0.00
- PTIX N/A
- Revenue
- APM N/A
- PTIX N/A
- Revenue This Year
- APM $157,729.10
- PTIX N/A
- Revenue Next Year
- APM N/A
- PTIX N/A
- P/E Ratio
- APM $345.64
- PTIX N/A
- Revenue Growth
- APM N/A
- PTIX N/A
- 52 Week Low
- APM $0.46
- PTIX $0.43
- 52 Week High
- APM $17.49
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- APM 47.12
- PTIX 39.26
- Support Level
- APM $1.21
- PTIX $0.43
- Resistance Level
- APM $1.30
- PTIX $0.52
- Average True Range (ATR)
- APM 0.75
- PTIX 0.05
- MACD
- APM -0.06
- PTIX -0.01
- Stochastic Oscillator
- APM 4.58
- PTIX 6.74
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.